Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Relief Therapeutics Holding S.A. (SIX: RLF, OTCQB: RLFTF)

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100TM is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. *

 

Period Start 2016-06-01 merged
  Group Relief Therapeutics (Group)
Products Industry pharmaceutical active protein
  Industry 2 aviptadil (NN)
Persons Person Selvaraju, Raghuram (Ram) (Relief Therapeutics 202010 Board Chairman)
  Person 2 Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group)
     
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 15 Avenue de Sécheron
Fondation EIP, Bâtiment F2/F3
  City 1202 Genève GE
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency CHF
  Profit -7,828,000 (2020-12-31)
  Cash 35,000,000 (2021-04-15)
     
    * Document for �About Section�: Relief Therapeutics Holding AG. (1/20/21). "Press Release: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil". Geneva & Gundelfingen.
     
   
Record changed: 2021-05-11

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Relief Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top